Deciphera Pharmaceuticals to Present Data from INTRIGUE Phase 3 Study of QINLOCK® (ripretinib) and Trial-in-Progress Poster for INSIGHT Pivotal Phase 3 Study of QINLOCK® at the 2023 American Society of Clinical Oncology Annual Meeting

– Company Presents Poster on Overall Survival and Long-Term Safety Results from INTRIGUE Study; Second Poster Presents Analysis from INTRIGUE Patients without Detectable ctDNA at Baseline... | May 25, 2023

Related Keywords

Germany ,Australia ,Israel ,Hong Kong ,Switzerland ,Chicago ,Illinois ,United States ,Macau ,United Kingdom ,Canada ,Taiwan ,China ,New Zealand ,German ,American ,West German ,Sebastian Bauer ,Jonathan Trent ,Suzanne George ,Robinl Jones ,Matthewl Sherman ,Translational Sarcoma Research ,Institute Of Cancer Research ,Deciphera Pharmaceuticals ,German Cancer Consortium ,Dana Farber Cancer Institute ,Deciphera Pharmaceuticals Inc ,University Duisburg ,Sarcoma Center ,Sylvester Comprehensive Cancer Center ,American Society Of Clinical Oncology ,Linkedin ,Nasdaq ,Exchange Commission ,Clinical Research ,European Union ,University Hospital Essen ,Head Of Sarcoma Center ,German Cancer Center ,University Of Miami Health System ,Clinical Oncology ,Annual Meeting ,Executive Vice President ,Chief Medical Officer ,Consultant Medical Oncologist ,Royal Marsden ,Cancer Research ,Discussion Session ,Associate Director ,Miami Health System ,Associate Division Chief ,Response Evaluation Criteria ,Solid Tumors ,West German Cancer Center ,University Duisburg Essen ,Rapid Abstract ,Private Securities Litigation Reform Act ,Quarterly Report ,Nc Stock Exchange ,News ,Information ,Press Release ,Company ,Presents ,Poster ,N ,Verall ,Survival ,End ,Safety ,Results ,Rom ,Intrigue ,Second ,Analysis ,Patients ,Without ,Mundetectable ,Ctdna ,T Dcph Us24344t1016 ,